Literature DB >> 9759797

Immunohistochemical characterization of cellular infiltrate in nasal polyp from aspirin-sensitive asthmatic patients.

H S Park1, D H Nahm, K Park, K S Suh, H E Yim.   

Abstract

BACKGROUND: The immunopathologic mechanism of nasal polyp in aspirin-sensitive asthma remains to be further defined.
OBJECTIVE: To characterize the features of the inflammatory cellular infiltrate in the nasal polyp tissue from aspirin-sensitive asthmatic patients.
METHODS: We have taken nasal polyp tissue during nasal polyp resection from 13 aspirin-sensitive asthma, 6 allergic, and 12 non-allergic subjects. Immunohistochemistry was employed to stain and enumerate the individual inflammatory cell types using monoclonal antibodies against tryptase (AA1) to identify mast cells, against secreted forms of eosinophil cationic protein (EG2), to identify activated eosinophils, against neutrophil elastase (NE) for neutrophils and against T cell surface markers (CD3) to identify total T cells.
RESULTS: There were no significant differences in AA1 + cells among three groups (P>.05). EG2 + cells tended to be higher in ASA-sensitive asthmatic patients than in allergic and non-allergic subjects, but no statistical significance was observed. NE+ cells were found in most subjects of the three groups and their numbers were significantly higher in allergic subjects than in aspirin-sensitive asthma (P<.05). Some patients had CD3+ cells with no statistical significance among the three groups. Significant correlation was found in numbers between NE+ cell and AA1+ cell (r=.44, P=.01), and between NE+ cell and EG2+ cell (r=.40, P=.02).
CONCLUSION: These findings suggested that major effector cells such as mast cells and eosinophils might be placed in the center of the inflammatory response of nasal polyps, regardless of their association with aspirin sensitivity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9759797     DOI: 10.1016/s1081-1206(10)62815-3

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  8 in total

Review 1.  Rhinosinusitis and nasal polyposis in aspirin sensitive and aspirin tolerant patients: are they different?

Authors:  M L Kowalski
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 2.  Eosinophils and Mast Cells in Aspirin-Exacerbated Respiratory Disease.

Authors:  John W Steinke; Spencer C Payne; Larry Borish
Journal:  Immunol Allergy Clin North Am       Date:  2016-09-13       Impact factor: 3.479

3.  Protection of leukotriene receptor antagonist against aspirin-induced bronchospasm in asthmatics.

Authors:  Jong Sook Park; An Soo Jang; Sung Woo Park; Young Mok Lee; Soo Taek Uh; Yong Hoon Kim; Ji Yean Cha; Se Min Park; Choon-Sik Park
Journal:  Allergy Asthma Immunol Res       Date:  2009-12-30       Impact factor: 5.764

4.  Galectin-10 is released in the nasal lavage fluid of patients with aspirin-sensitive respiratory disease.

Authors:  Ma Cristina Negrete-Garcia; Carla Yoneli Jiménez-Torres; Noe Alvarado-Vásquez; A Rosalía Montes-Vizuet; J R Velázquez-Rodriguez; M Carmen Jimenez-Martinez; Luis Manuel Teran-Juárez
Journal:  ScientificWorldJournal       Date:  2012-04-30

Review 5.  Pathogenesis of nasal polyps: an update.

Authors:  Rafal Pawliczak; Anna Lewandowska-Polak; Marek L Kowalski
Journal:  Curr Allergy Asthma Rep       Date:  2005-11       Impact factor: 4.919

Review 6.  Emerging Biomarkers Beyond Leukotrienes for the Management of Nonsteroidal Anti-inflammatory Drug (NSAID)-Exacerbated Respiratory Disease.

Authors:  Hyo-In Rhyou; Young-Hee Nam; Hae-Sim Park
Journal:  Allergy Asthma Immunol Res       Date:  2022-03       Impact factor: 5.764

Review 7.  Potential Biomarkers for NSAID-Exacerbated Respiratory Disease.

Authors:  Hanki Park; Youngwoo Choi; Chang-Gyu Jung; Hae-Sim Park
Journal:  Mediators Inflamm       Date:  2017-08-09       Impact factor: 4.711

Review 8.  Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease.

Authors:  Esha Sehanobish; Mohammad Asad; Mali Barbi; Steven A Porcelli; Elina Jerschow
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.